research – The Mulhouse Hematology and Transfusion Research Institute (IRHT) is on the verge of developing a “rapid and less invasive” technique to identify the type of brain cancer without having to do a biopsy
On the battlefield against cancer, research does not lack inventiveness and perseverance. This time, it’s happening in Mulhouse (Haut-Rhin), at the Mulhouse Research Institute of Hematology and Transplantation (IRHT). The latter is working to develop a “simple” technique that makes it possible to identify what type of brain cancer we are dealing with, to diagnose it quickly and in a less invasive way.
Called “DiaBioLiq” (Diagnosis by liquid biopsy), their project of 1.8 million euros over three years, which notably required the essential purchase of a new high-throughput sequencer to establish a database, seeks to develop a diagnostic kit that can be used by hospitals and their healthcare professionals.
An aggressive cancer
Targeted research which takes on its full importance when we know that brain cancers represent 1 to 1.5% of new cancers diagnosed each year in France (Source Inca), or 5,000 to 6,000 people (55% of whom are men). And it is no more reassuring to know that it is an aggressive cancer, the survival rate for this pathology being only 30% currently alo(…) Read more on 20minutes
Read also :
Why “circulating DNA” is a new weapon in the diagnosis and monitoring of cancers
“Miss AI”: Will artificial intelligence further worsen female beauty stereotypes?
Bladder cancer may be more dangerous in women
United States: Suffering from cancer, he seeks a “good doctor” after winning $1.3 billion
